Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: New effect of asymmetric dimethylarginine

Kidney International

Volumn 81, Issue 8, 2012, Pages 762-768

  Kajimoto, Hidemi ^a   Kai, Hisashi ^b   Aoki, Hiroki ^a   Yasuoka, Suguru ^b   Anegawa, Takahiro ^b   Aoki, Yuji ^b   Ueda, Seiji ^b   Okuda, Seiya ^b   Imaizumi, Tsutomu ^a,b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

asymmetric dimethylarginine; chronic kidney disease; endothelial dysfunction; nitric oxide synthase; signal transduction

Indexed keywords

CREATININE; DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITROGEN; SERINE; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY FAILURE; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; UREA NITROGEN BLOOD LEVEL;

EID: 84859424328     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.476     Document Type: Article

References (35)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
2. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340. (Pubitemid 40139112)
3. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047. (Pubitemid 44036188)
4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119. (Pubitemid 28527268)
5. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169. (Pubitemid 37337595)
6. Culleton BF, Larson MG, Wilson PW et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-2219. (Pubitemid 30004750)
7. Stam F, van Guldener C, Becker A et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006; 17: 537-545.
8. Leiper J, Vallance P. Biological significance of endogenous methlarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-548. (Pubitemid 29369253)
9. Cam TL, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003; 4: 33-40. (Pubitemid 38234493)
10. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-1030. (Pubitemid 38737826)
11. Zoccali C. Asymmeteric dimethlarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24: 611-619.
12. McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976; 154: 179-184.
13. Ogawa T, Kimoto M, Watanabe H et al. Metabolism of NG,NG-and NG,N0G-dimethylarginine in rats. Arch Biochem Biophys 1987; 252: 526-537.
14. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-1030. (Pubitemid 38737826)
15. Boger RH. The pharmacodynamics of L-arginine. J Nutr 2007; 137: 1650S-1655S. (Pubitemid 46855525)
16. Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
17. Cross JM, Donald AE, Kharbanda R et al. Acute administration of Larginine does not improve arterial endothelial function in chronic renal failure. Kidney Int 2001; 60: 2318-2323. (Pubitemid 33070474)
18. Hasegawa K, Wakino S, Tatematsu S et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res 2007; 101: e2-10.
19. Smith CL, Anthony S, Hubank M et al. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med 2005; 2: e264.
20. Miyazaki H, Matsuoka H, Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146. (Pubitemid 29120084)
21. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59: 824-833. (Pubitemid 38366238)
22. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117. (Pubitemid 34094901)
23. Kielstein JT, Boger RH, Bode-Boger SM et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176. (Pubitemid 34042024)
24. Wever R, Boer P, Hijmering M et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999; 19: 1168-1172. (Pubitemid 29227634)
25. Passauer J, Pistrosch F, Bussemaker E et al. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 2005; 16: 959-965. (Pubitemid 41710306)
26. Hasdan G, Benchetrit S, Rashid G et al. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 2002; 61: 586-590. (Pubitemid 34102600)
27. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res 2007; 75: 247-260. (Pubitemid 46961923)
28. Dayoub H, Achan V, Adimoolam S et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003; 108: 3042-3047. (Pubitemid 37553576)
29. Jacobi J, Sydow K, von Degenfeld G et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111: 1431-1438. (Pubitemid 40396810)
30. Tanaka M, Sydow K, Gunawan F et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112: 1549-1556. (Pubitemid 41324515)
31. Chauntin A, Ferris E. Experimental renal insufficiency produced by partial nephrectomy. Arch Intern Med 1932; 49: 767-787.
32. Ueda S, Kato S, Matsuoka H et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92: 226-233. (Pubitemid 36254279)
33. Green LC, Wagner DA, Glogowski J et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-138. (Pubitemid 13203451)
34. Dayoub H, Rodionov RN, Lynch C et al. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke 2008; 39: 180-184.
35. Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist0s perspective. Trends Pharmacol Sci 1995; 16: 18-22.